Item 1.01 중요

중요 계약 체결

Item 1.01. Entry into a Material Definitive Agreement.   On October 1, 2026, Regeneron Pharmaceuticals, Inc., a New York corporation (“ Regeneron ” or the “ Company ”), Sanofi Biotechnology SAS, a société par actions simplifée organized under the laws of France (“ Sanofi Biotechnology ”), and Sanofi, a société anonyme organized under the laws of France (“ Sanofi Parent ” and, with Sanofi Biotechnology, “ Sanofi ”), entered into the Sixth Amendmen...

Item 2.02 매우중요

실적 발표

Item 2.02. Results of Operations and Financial Condition.   Regeneron currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“ GAAP ”) and its non-GAAP financial results for the third quarter 2026 will include an acquired in-process research and development (“ IPR&D ”) charge of approximately $22 million on a pre-tax basis. The acquired IPR&D charge is expected to negatively impact each of GAAP and non-GAAP net income per dilu...

Item 8.01

기타 이벤트

리제네론과 산노피가 6차 수정안 체결과 함께 합의금 계약을 체결했다. 리제네론은 듀픽센트 상용화 관련 정보 접근 및 감시 권리에 대한 산노피 상대 소송을 취하했다.